An update on the cardiovascular effects of quercetin, a plant flavonoid

Current Nutrition and Food Science

Volumn 10, Issue 1, 2014, Pages 36-48

  Islam, Mohammed A ^a   Schmidt, Robert W ^b   Gunaseelan, Simi ^a   Sanchez, Anthony ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

Antioxidants; Atherosclerosis; Cardiovascular disease; Dyslipidemia; Endothelial function; Formulations; Oxidative stress; Plant flavonoid; Quercetin

Indexed keywords

BIOFLAVONOID; BIOLOGICAL MARKER; CHOLESTEROL; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; HEME OXYGENASE 1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL 1,4,5 TRISPHOSPHATE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEUKOTRIENE B4; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PHOSPHOLIPID; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SERUM AMYLOID A; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ANTICOAGULATION; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY FLUID; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STABILITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; IC 50; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; VASCULITIS;

EID: 84897402994     PISSN: 15734013     EISSN: 22123881     Source Type: Journal    
DOI: 10.2174/157340131001140328115216     Document Type: Review

References (186)

1. WHO. Global atlas on cardiovascular disease prevention and con trol. Editors: World Heart Federation; World Stroke Organization 2011.
2. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-e215.
3. Heron M, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009; 57: 1-134.
4. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009; 6: 399-409.
5. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
6. Hertog MG, Feskens EJ, Kromhout D. Antioxidant flavonols and coronary heart disease risk. Lancet 1997; 349: 699
7. Hertog MG, Feskens EJ, Hollman PC, et al. Dietary flavonoids and cancer risk in the Zutphen Elderly Study. Nutr Cancer 1994; 22: 175-84.
8. Hertog MG, Feskens EJ, Hollman PC, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993; 342: 1007-11.
9. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr 2003; 57: 904-8.
10. Hollman PC, Geelen A, Kromhout D. Dietary flavonol intake may lower stroke risk in men and women. J Nutr 2010; 140: 600-4.
11. Formica JV, Regelson W. Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol 1995; 33: 1061-80.
12. Arts IC, Hollman PC. Polyphenols and disease risk in epidemi-ologic studies. Am J Clin Nutr 2005; 81: 317S-25S.
13. Arai Y, Watanabe S, Kimira M, et al. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 2000; 130: 2243-50.
14. Hertog MG, Hollman PC, Katan MB, Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 1993; 20: 21-9.
15. de Vries JH, Janssen PL, Hollman PC, et al. Consumption of quer-cetin and kaempferol in free-living subjects eating a variety of diets. Cancer Lett 1997; 114: 141-4.
16. Justesen U, Knuthsen P, Leth T. Determination of plant polyphe-nols in Danish foodstuffs by HPLC-UV and LC-MS detection. Cancer Lett 1997; 114 165-7
17. Hollman PC, Hertog MG, Katan MB. Role of dietary flavonoids in protection against cancer and coronary heart disease. Biochem Soc Trans 1996; 24: 785-9.
18. Erlund I, Kosonen T, Alfthan G, et al. Pharmacokinetics of quer-cetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 2000; 56: 545-53.
19. Spencer JP, Kuhnle GG, Williams RJ, Rice-Evans C. Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites. Biochem J 2003; 372: 173-81.
20. Bieger J, Cermak R, Blank R, et al. Tissue distribution of quercetin in pigs after long-term dietary supplementation. J Nutr 2008; 138: 1417-20.
21. Conquer JA, Maiani G, Azzini E, et al. Supplementation with quer-cetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J Nutr 1998; 128: 593-7.
22. Perez-Vizcaino F, Duarte J. Flavonols and cardiovascular disease. Mol Aspects Med 2010; 31: 478-94.
23. Hodgson JM. Tea flavonoids and cardiovascular disease. Asia Pac J Clin Nutr 2008; 17: Suppl 1 288-90
24. Peluso MR. Flavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, and modulate lipid homeostasis in adipose tissue and liver. Exp Biol Med (Maywood) 2006; 231: 1287-99.
25. Terao J, Kawai Y, Murota K. Vegetable flavonoids and cardiovascular disease. Asia Pac J Clin Nutr 2008; 17: 291-3.
26. Islam MA. Cardiovascular effects of green tea catechins: progress and promise. Recent Pat Cardiovasc Drug Discov 2012; 7: 88-99.
27. Larson AB, Guo Y, Gale D, et al. Acute quercetin supplementation does not lower blood pressure or ACE activity in normotensive males. J Am Diet Assoc 2009; 109: 16.
28. Knab AM, Shanely RA, Henson DA, et al. Influence of quercetin supplementation on disease risk factors in community-dwelling adults. J Am Diet Assoc 2011; 111: 542-9.
29. Lee KH, Park E, Lee HJ, et al. Effects of daily quercetin-rich supplementation on cardiometabolic risks in male smokers. Nutr Res Pract 2011; 5: 28-33.
30. Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled crossover study. Br J Nutr 2009; 102: 1065-74.
31. Egert S, Boesch-Saadatmandi C, Wolffram S, et al. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 2010; 140: 278-84.
32. Edwards RL, Lyon T, Litwin SE, et al. Quercetin reduces blood pressure in hypertensive subjects. J Nutr 2007; 137: 2405-11.
33. Alwaili K, Awan Z, Alshahrani A, Genest J. High-density lipopro-teins and cardiovascular disease: 2010 update. Expert Rev Cardio-vasc Ther 2010; 8: 413-23.
34. Badimon L, Vilahur G. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus throm-botic chaos. Ann N Y Acad Sci 2012; 1254: 18-32.
35. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011; 13: 544-52.
36. Pfeuffer M, Auinger A, Bley U, et al. Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammatory parameters in men with different APOE isoforms. Nutr Metab Car-diovasc Dis 2011; 23; 403-9.
37. Larmo PS, Yang B, Hurme SA, et al. Effect of a low dose of sea buckthorn berries on circulating concentrations of cholesterol, tria-cylglycerols, and flavonols in healthy adults. Eur J Nutr 2009; 48: 277-82.
38. Boots AW, Drent M, de Boer VC, et al. Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr 2011; 30: 506-12.
39. Janssen K, Mensink RP, Cox FJ, et al. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. Am J Clin Nutr 1998; 67: 255-62.
40. Fichtlscherer S, Breuer S, Schachinger V, et al. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J 2004; 25: 1412-8.
41. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-25.
42. Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009; 73: 595-601.
43. Wojakowski W, Gminski J. Soluble ICAM-1, VCAM-1 and E-selectin in children from families with high risk of atherosclerosis. Int J Mol Med 2001; 7: 181-5.
44. Vita JA, Keaney JF, Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 2002; 106: 640-2.
45. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 2003; 93: 388-98.
46. Brevetti G, Martone VD, de CT, et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost 2001; 85: 63-6.
47. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-6.
48. Blann AD. Is raised von Willebrand factor a marker of endothelial cell damage? Med Hypotheses 1993; 41: 419-24.
49. Omland T, Lie RT, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myo-cardial infarction. Circulation 1994; 89: 1573-9.
50. Duarte J, Perez-Vizcaino F, Zarzuelo A, et al. Vasodilator effects of quercetin in isolated rat vascular smooth muscle. Eur J Pharmacol 1993; 239: 1-7.
51. Khoo NK, White CR, Pozzo-Miller L, et al. Dietary flavonoid quercetin stimulates vasorelaxation in aortic vessels. Free Radic Biol Med 2010; 49: 339-47.
52. Li PG, Sun L, Han X, et al. Quercetin induces rapid eNOS phos-phorylation and vasodilation by an Akt-independent and PKA-dependent mechanism. Pharmacology 2012; 89: 220-8.
53. Ibarra M, Perez-Vizcaino F, Cogolludo A, et al. Cardiovascular effects of isorhamnetin and quercetin in isolated rat and porcine vascular smooth muscle and isolated rat atria. Planta Med 2002; 68: 307-10.
54. Perez-Vizcaino F, Ibarra M, Cogolludo AL, et al. Endothelium-independent vasodilator effects of the flavonoid quercetin and its methylated metabolites in rat conductance and resistance arteries. J Pharmacol Exp Ther 2002; 302: 66-72.
55. Menendez C, Jimenez R, Moreno L, et al. Lack of synergistic interaction between quercetin and catechin in systemic and pulmonary vascular smooth muscle. Br J Nutr 2011; 105: 1287-93.
56. Chiwororo WD, Ojewole JA. Dual effect of quercetin on rat isolated portal vein smooth muscle contractility. Cardiovasc J Afr 2010; 21: 132-6.
57. Machha A, Mustafa MR. Chronic treatment with flavonoids prevents endothelial dysfunction in spontaneously hypertensive rat aorta. J Cardiovasc Pharmacol 2005; 46: 36-40.
58. Roghani M, Baluchnejadmojarad T, Vaez-Mahdavi MR, Roghani-Dehkordi F. Mechanisms underlying quercetin-induced vasorelaxa-tion in aorta of subchronic diabetic rats: an in vitro study. Vascul Pharmacol 2004; 42: 31-5.
59. Duarte J, Perez VF, Utrilla P, et al. Vasodilatory effects of flavon-oids in rat aortic smooth muscle. Structure-activity relationships. Gen Pharmacol 1993; 24: 857-62.
60. Lodi F, Jimenez R, Moreno L, et al. Glucuronidated and sulfated metabolites of the flavonoid quercetin prevent endothelial dysfunction but lack direct vasorelaxant effects in rat aorta. Atherosclerosis 2009; 204: 34-9.
61. Suri S, Liu XH, Rayment S, et al. Quercetin and its major metabolites selectively modulate cyclic GMP-dependent relaxations and associated tolerance in pig isolated coronary artery. Br J Pharmacol 2010; 159: 566-75.
62. Benito S, Lopez D, Saiz MP, et al. A flavonoid-rich diet increases nitric oxide production in rat aorta. Br J Pharmacol 2002; 135: 910-6.
63. Duarte J, Perez-Palencia R, Vargas F, et al. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol 2001; 133: 117-24.
64. Galisteo M, Garcia-Saura MF, Jimenez R, et al. Effects of quer-cetin treatment on vascular function in deoxycorticosterone acetate-salt hypertensive rats. Comparative study with verapamil. Planta Med 2004; 70: 334-41.
65. Garcia-Saura MF, Galisteo M, Villar IC, et al. Effects of chronic quercetin treatment in experimental renovascular hypertension. Mol Cell Biochem 2005; 270: 147-55.
66. Sanchez M, Galisteo M, Vera R, et al. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 2006; 24: 75-84.
67. Al-Shalmani S, Suri S, Hughes DA, et al. Quercetin and its principal metabolites, but not myricetin, oppose lipopolysaccharide-induced hyporesponsiveness of the porcine isolated coronary artery. Br J Pharmacol 2011; 162: 1485-97.
68. Bourque SL, Davidge ST, Adams MA. The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol Regul Integr Comp Physiol 2011; 300: R1288-R1295.
69. Brunner F, Bras-Silva C, Cerdeira AS, Leite-Moreira AF. Cardiovascular endothelins: essential regulators of cardiovascular homeo-stasis. Pharmacol Ther 2006; 111: 508-31.
70. Ruef J, Moser M, Kubler W, Bode C. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol 2001; 10: 311-5.
71. Loke WM, Proudfoot JM, Hodgson JM, et al. Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction. Ar-terioscler Thromb Vasc Biol 2010; 30: 749-57.
72. Nicholson SK, Tucker GA, Brameld JM. Physiological concentrations of dietary polyphenols regulate vascular endothelial cell expression of genes important in cardiovascular health. Br J Nutr 2010; 103: 1398-403.
73. Nicholson SK, Tucker GA, Brameld JM. Effects of dietary poly-phenols on gene expression in human vascular endothelial cells. Proc Nutr Soc 2008; 67: 42-7.
74. Romero M, Jimenez R, Sanchez M, et al. Quercetin inhibits vascular superoxide production induced by endothelin-1: Role of NADPH oxidase, uncoupled eNOS and PKC. Atherosclerosis 2009; 202: 58-67.
75. Triggle CR, Samuel SM, Ravishankar S, et al. The endothelium: influencing vascular smooth muscle in many ways. Can J Physiol Pharmacol 2012; 90: 713-38.
76. Nicholson SK, Tucker GA, Brameld JM. Physiological concentrations of dietary polyphenols regulate vascular endothelial cell expression of genes important in cardiovascular health. Br J Nutr 2010; 103: 1398-403.
77. Tuttolomondo A, Di RD, Pecoraro R, et al. Atherosclerosis as an inflammatory disease. Curr Pharm Des 2012; 18: 4266-88.
78. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718-23.
79. Kevil CG, Patel RP, Bullard DC. Essential role of ICAM-1 in mediating monocyte adhesion to aortic endothelial cells. Am J Physiol Cell Physiol 2001; 281: C1442-C1447.
80. Crespo I, Garcia-Mediavilla MV, Gutierrez B, et al. A comparison of the effects of kaempferol and quercetin on cytokine-induced pro-inflammatory status of cultured human endothelial cells. Br J Nutr 2008; 100: 968-76.
81. Gerritsen ME, Carley WW, Ranges GE, et al. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am J Pathol 1995; 147: 278-92.
82. Kleemann R, Verschuren L, Morrison M, et al. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 2011; 218: 44-52.
83. Kobuchi H, Roy S, Sen CK, et al. Quercetin inhibits inducible ICAM-1 expression in human endothelial cells through the JNK pathway. Am J Physiol 1999; 277: C403-C411.
84. Lotito SB, Frei B. Dietary flavonoids attenuate tumor necrosis factor alpha-induced adhesion molecule expression in human aortic endothelial cells. Structure-function relationships and activity after first pass metabolism. J Biol Chem 2006; 281: 37102-10.
85. Chen YC, Shen SC, Lee WR, et al. Inhibition of nitric oxide syn-thase inhibitors and lipopolysaccharide induced inducible NOS and cyclooxygenase-2 gene expressions by rutin, quercetin, and quer-cetin pentaacetate in RAW 264.7 macrophages. J Cell Biochem 2001; 82: 537-48.
86. Kim HP, Mani I, Iversen L, Ziboh VA. Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxy-genase and lipoxygenase from guinea-pigs. Prostaglandins Leukot Essent Fatty Acids 1998; 58: 17-24.
87. Lee JH, Kim GH. Evaluation of antioxidant and inhibitory activities for different subclasses flavonoids on enzymes for rheumatoid arthritis. J Food Sci 2010; 75: H212-H217.
88. Jala VR, Haribabu B. Leukotrienes and atherosclerosis: new roles for old mediators. Trends Immunol 2004; 25: 315-22.
89. Back M, Bu DX, Branstrom R, et al. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 2005; 102: 17501-6.
90. Sanbongi C, Suzuki N, Sakane T. Polyphenols in chocolate, which have antioxidant activity, modulate immune functions in humans in vitro. Cell Immunol 1997; 177: 129-36.
91. Stocker R, Perrella MA. Heme oxygenase-1: a novel drug target for atherosclerotic diseases? Circulation 2006; 114: 2178-89.
92. Lotito SB, Zhang WJ, Yang CS, et al. Metabolic conversion of dietary flavonoids alters their anti-inflammatory and antioxidant properties. Free Radic Biol Med 2011; 51: 454-63.
93. Koga T, Meydani M. Effect of plasma metabolites of (+)-catechin and quercetin on monocyte adhesion to human aortic endothelial cells. Am J Clin Nutr 2001; 73: 941-8.
94. Collins T, Read MA, Neish AS, et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995; 9: 899-909.
95. Choi JS, Choi YJ, Park SH, et al. Flavones mitigate tumor necrosis factor-alpha-induced adhesion molecule upregulation in cultured human endothelial cells: role of nuclear factor-kappa B. J Nutr 2004; 134: 1013-9.
96. Winrow VR, Winyard PG, Morris CJ, Blake DR. Free radicals in inflammation: second messengers and mediators of tissue destruction. Br Med Bull 1993; 49: 506-22.
97. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 2006; 11: 524-33.
98. Guzik TJ, Griendling KK. NADPH oxidases: molecular understanding finally reaching the clinical level? Antioxid Redox Signal 2009; 11: 2365-70.
99. Szuldrzynski K, Zalewski J, Machnik A, Zmudka K. Elevated levels of 8-iso-prostaglandin F2alpha in acute coronary syndromes are associated with systemic and local platelet activation. Pol Arch Med Wewn 2010; 120: 19-24.
100. Mythri RB, Venkateshappa C, Harish G, et al. Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem Res 2011; 36: 1452-63.
101. Alia M, Mateos R, Ramos S, et al. Influence of quercetin and rutin on growth and antioxidant defense system of a human hepatoma cell line (HepG2). Eur J Nutr 2006; 45: 19-28.
102. Holland JA, O'Donnell RW, Chang MM, et al. Endothelial cell oxidant production: effect of NADPH oxidase inhibitors. Endothe-lium 2000; 7: 109-19.
103. Redondo A, Estrella N, Lorenzo AG, et al. Quercetin and catechin synergistically inhibit angiotensin II-induced redox-dependent signalling pathways in vascular smooth muscle cells from hypertensive rats. Free Radic Res 2012; 46: 619-27.
104. Manea A, Simionescu M. Nox enzymes and oxidative stress in atherosclerosis. Front Biosci (Schol Ed) 2012; 4: 651-70.
105. Amic D, Davidovic-Amic D, Beslo D, et al. SAR and QSAR of the antioxidant activity of flavonoids. Curr Med Chem 2007; 14: 827-45.
106. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 2008; 585: 325-37.
107. Yi L, Chen CY, Jin X, et al. Differential suppression of intracellu-lar reactive oxygen species-mediated signaling pathway in vascular endothelial cells by several subclasses of flavonoids. Biochimie 2012; 94: 2035-44.
108. Terao J, Piskula MK. Flavonoids and membrane lipid peroxidation inhibition. Nutrition 1999; 15: 790-1.
109. Cao G, Sofic E, Prior RL. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radic Biol Med 1997; 22: 749-60.
110. Kawai Y, Nishikawa T, Shiba Y, et al. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J Biol Chem 2008; 283: 9424-34.
111. Ishizawa K, Yoshizumi M, Kawai Y, et al. Pharmacology in health food: metabolism of quercetin in vivo and its protective effect against arteriosclerosis. J Pharmacol Sci 2011; 115: 466-70.
112. Terao J, Kawai Y, Murota K. Vegetable flavonoids and cardiovascular disease. Asia Pac J Clin Nutr 2008; 17(Suppl 1): 291-3.
113. Menendez C, Duenas M, Galindo P, et al. Vascular deconjugation of quercetin glucuronide: the flavonoid paradox revealed? Mol Nutr Food Res 2011; 55: 1780-90.
114. Azuma K, Minami Y, Ippoushi K, Terao J. Lowering effects of onion intake on oxidative stress biomarkers in streptozotocin-induced diabetic rats. J Clin Biochem Nutr 2007; 40: 131-40.
115. Kosinova P, Berka K, Wykes M, et al. Positioning of antioxidant quercetin and its metabolites in lipid bilayer membranes: implication for their lipid-peroxidation inhibition. J Phys Chem B 2012; 116: 1309-18.
116. Ostroumova OS, Efimova SS, Schagina LV. Probing amphotericin B single channel activity by membrane dipole modifiers. PLoS One 2012; 7: e30261.
117. Jeong YJ, Choi YJ, Choi JS, et al. Attenuation of monocyte adhesion and oxidised LDL uptake in luteolin-treated human endothelial cells exposed to oxidised LDL. Br J Nutr 2007; 97: 447-57.
118. Kostyuk VA, Potapovich AI, Suhan TO, et al. Antioxidant and signal modulation properties of plant polyphenols in controlling vascular inflammation. Eur J Pharmacol 2011; 658: 248-56.
119. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001; 15: 2073-84.
120. Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-9.
121. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-4.
122. Leckey LC, Garige M, Varatharajalu R, et al. Quercetin and etha-nol attenuate the progression of atherosclerotic plaques with concomitant up regulation of paraoxonase1 (PON1) gene expression and PON1 activity in LDLR-/- mice. Alcohol Clin Exp Res 2010; 34: 1535-42.
123. Nickel T, Hanssen H, Sisic Z, et al. Immunoregulatory effects of the flavonol quercetin in vitro and in vivo. Eur J Nutr 2011; 50: 163-72.
124. Doring Y, Zernecke A. Plasmacytoid dendritic cells in atherosclerosis. Front Physiol 2012; 3: 230.
125. Murota K, Hotta A, Ido H, et al. Antioxidant capacity of albumin-bound quercetin metabolites after onion consumption in humans. J Med Invest 2007; 54: 370-4.
126. Janisch KM, Williamson G, Needs P, Plumb GW. Properties of quercetin conjugates: modulation of LDL oxidation and binding to human serum albumin. Free Radic Res 2004; 38: 877-84.
127. Gamba P, Leonarduzzi G, Tamagno E, et al. Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-beta in amplifying neuronal damage in Alzheimer's disease: three partners in crime. Aging Cell 2011; 10: 403-17.
128. Sanchez-Gallego JI, Lopez-Revuelta A, Hernandez-Hernandez A, et al. Comparative antioxidant capacities of quercetin and butylated hydroxyanisole in cholesterol-modified erythrocytes damaged by tert-butylhydroperoxide. Food Chem Toxicol 2011; 49: 2212-21.
129. Ghaffari MA, Mojab S. Influence of flavonols as in vitro on low density lipoprotein glycation. Iran Biomed J 2007; 11: 185-91.
130. Vorchheimer DA, Becker R. Platelets in atherothrombosis. Mayo Clin Proc 2006; 81: 59-68.
131. Shi G, Morrell CN. Platelets as initiators and mediators of inflammation at the vessel wall. Thromb Res 2011; 127: 387-90.
132. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-61.
133. Bucki R, Pastore JJ, Giraud F, et al. Flavonoid inhibition of platelet procoagulant activity and phosphoinositide synthesis. J Thromb Haemost 2003; 1: 1820-8.
134. Crescente M, Jessen G, Momi S, et al. Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level. Functional and modelling studies. Thromb Haemost 2009; 102: 336-46.
135. Navarro-Nunez L, Rivera J, Guerrero JA, et al. Differential effects of quercetin, apigenin and genistein on signalling pathways of pro-tease-activated receptors PAR(1) and PAR(4) in platelets. Br J Pharmacol 2009; 158: 1548-56.
136. Tzeng SH, Ko WC, Ko FN, Teng CM. Inhibition of platelet aggregation by some flavonoids. Thromb Res 1991; 64: 91-100.
137. Sheu JR, Hsiao G, Chou PH, et al. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets. J Agric Food Chem 2004; 52: 4414-8.
138. Guglielmone HA, Agnese AM, Nunez Montoya SC, Cabrera JL. Inhibitory effects of sulphated flavonoids isolated from Flaveria bi-dentis on platelet aggregation. Thromb Res 2005; 115: 495-502.
139. Gryglewski RJ, Korbut R, Robak J, Swies J. On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol 1987; 36: 317-22.
140. Lin HC, Liu HW, Lin CN, Teng CM. Inhibition of thromboxane formation as the antiplatelet mechanism of 3,4-dihydroxyxanthone and quercetin pentaacetate. Gaoxiong Yi Xue Ke Xue Za Zhi 1991; 7: 505-12.
141. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and proco-agulant function. Blood 2009; 114: 663-6.
142. Mariee AD, Abd-Allah GM, El-Beshbishy HA. Protective effect of dietary flavonoid quercetin against lipemic-oxidative hepatic injury in hypercholesterolemic rats. Pharm Biol 2012; 50: 1019-25.
143. Prince PS, Sathya B. Pretreatment with quercetin ameliorates lip-ids, lipoproteins and marker enzymes of lipid metabolism in isopro-terenol treated cardiotoxic male Wistar rats. Eur J Pharmacol 2010; 635: 142-8.
144. Yugarani T, Tan BK, Teh M, Das NP. Effects of polyphenolic natural products on the lipid profiles of rats fed high fat diets. Lipids 1992; 27: 181-6.
145. Zhao L, Wu J, Wang Y, et al. Cholesterol metabolism is modulated by quercetin in rats. J Agric Food Chem 2011; 59: 1104-8.
146. Aviram M, Rosenblat M, Billecke S, et al. Human serum par-aoxonase (PON 1) is inactivated by oxidized low density lipopro-tein and preserved by antioxidants. Free Radic Biol Med 1999; 26: 892-904.
147. Gong M, Garige M, Varatharajalu R, et al. Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation. Biochem Biophys Res Commun 2009; 379: 1001-4.
148. Dali-Youcef N, Mecili M, Ricci R, Andres E. Metabolic inflammation: Connecting obesity and insulin resistance. Ann Med 2012;
149. Morel O, Kessler L, Ohlmann P, Bareiss P. Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombo-sis. Atherosclerosis 2010; 212: 367-76.
150. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl 2): S14-S21.
151. Li YQ, Zhou FC, Gao F, Bian JS, and Shan F. Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of alpha-glucosidase. J Agric Food Chem 2009; 57: 11463-11468.
152. Vlachodimitropoulou E, Sharp PA, Naftalin RJ. Quercetin-iron chelates are transported via glucose transporters. Free Radic Biol Med 2011; 50: 934-44.
153. Strobel P, Allard C, Perez-Acle T, et al. Myricetin, quercetin and catechin-gallate inhibit glucose uptake in isolated rat adipocytes. Biochem J 2005; 386: 471-8.
154. Cho JM, Chang SY, Kim DB, et al. Effects of physiological quer-cetin metabolites on interleukin-1beta-induced inducible NOS expression. J Nutr Biochem 2012; 23: 1394-402.
155. Kanter M, Aktas C, Erboga M. Protective effects of quercetin against apoptosis and oxidative stress in streptozotocin-induced diabetic rat testis. Food Chem Toxicol 2012; 50: 719-25.
156. Roger VL. Epidemiology of myocardial infarction. Med Clin North Am 2007; 91: 537-52.
157. Bolli R, Marban E. Molecular and cellular mechanisms of myocar-dial stunning. Physiol Rev 1999; 79: 609-34.
158. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006; 70: 181-90.
159. Ikizler M, Erkasap N, Dernek S, et al. Dietary polyphenol quercetin protects rat hearts during reperfusion: enhanced antioxidant capacity with chronic treatment. Anadolu Kardiyol Derg 2007; 7: 404-10.
160. Bartekova M, Carnicka S, Pancza D, et al. Acute treatment with polyphenol quercetin improves postischemic recovery of isolated perfused rat hearts after global ischemia. Can J Physiol Pharmacol 2010; 88: 465-71.
161. Bhandary B, Piao CS, Kim DS, et al. The protective effect of rutin against ischemia/reperfusion-associated hemodynamic alteration through antioxidant activity. Arch Pharm Res 2012; 35: 1091-7.
162. Huk I, Brovkovych V, Nanobash VJ, et al. Bioflavonoid quercetin scavenges superoxide and increases nitric oxide concentration in ischaemia-reperfusion injury: an experimental study. Br J Surg 1998; 85: 1080-5.
163. Afanas'Ev IB, Dorozhko AI, Brodskii AV, et al. Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. Biochem Pharmacol 1989; 38: 1763-9.
164. Nugroho A, Lim SC, Lee CM, et al. Simultaneous quantitative determination and validation of quercetin glycosides with per-oxynitrite-scavenging effects from Saussurea grandifolia. J Pharm Biomed Anal 2012; 61: 247-51.
165. Wan LL, Xia J, Ye D, et al. Effects of quercetin on gene and protein expression of NOX and NOS after myocardial ischemia and reperfusion in rabbit. Cardiovasc Ther 2009; 27: 28-33.
166. Graefe EU, Wittig J, Mueller S, et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001; 41: 492-9.
167. Erdman JW, Jr., Balentine D, Arab L, et al. Flavonoids and heart health: proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC. J Nutr 2007; 137: 718S-37S.
168. Moon JH, Nakata R, Oshima S, et al. Accumulation of quercetin conjugates in blood plasma after the short-term ingestion of onion by women. Am J Physiol Regul Integr Comp Physiol 2000; 279: R461-R467.
169. Alcocer F, Whitley D, Salazar-Gonzalez JF, et al. Quercetin inhibits human vascular smooth muscle cell proliferation and migration. Surgery 2002; 131: 198-204.
170. Tribolo S, Lodi F, Connor C, et al. Comparative effects of quer-cetin and its predominant human metabolites on adhesion molecule expression in activated human vascular endothelial cells. Atherosclerosis 2008; 197: 50-6.
171. Gugler R, Leschik M, Dengler HJ. Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol 1975; 9: 229-34.
172. Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 1995; 62:1276-82.
173. Hollman PC, van Trijp JM, Buysman MN, et al. Relative bioavail-ability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett 1997; 418: 152-6.
174. Kaminaga Y, Nagatsu A, Akiyama T, et al. Production of unnatural glucosides of curcumin with drastically enhanced water solubility by cell suspension cultures of Catharanthus roseus. FEBS Lett 2003; 555: 311-16.
175. Shimoi K, Yoshizumi K, Kido T, Usui Y, Yumoto T. Absorption and urinary excretion of quercetin, rutin, and alphaG-rutin, a water soluble flavonoid, in rats. J Agric Food Chem 2003; 51: 2785-9.
176. G-alpha-D-glucopyranosyl-rutin. Agric Biol Chem 1991; 55:181-7.
177. Makino T, Shimizu R, Kanemaru M, et al. Enzymatically modified isoquercitrin, alpha-oligoglucosyl quercetin 3-O-glucoside, is absorbed more easily than other quercetin glycosides or aglycone after oral administration in rats. Biol Pharm Bull 2009; 32: 2034-40.
178. Murota K, Matsuda N, Kashino Y, et al. alpha-Oligoglucosylation of a sugar moiety enhances the bioavailability of quercetin gluco-sides in humans. Arch Biochem Biophys 2010; 501: 91-97.
179. Nielsen IL, Chee WS, Poulsen L, et al. Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. J Nutr 2006; 136: 404-8.
180. Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost 2004; 2: 2138-45.
181. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 2009; 133(3): 238-44.
182. Jain AK, Thanki K, Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: Implications on oral bioavail-ability, antitumor efficacy and drug induced toxicity. Mol Pharma-ceut 2013; 10: 3459-74.
183. Jain S, Jain AK, Pohekar M, Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: Implications for drug-induced cardiotoxicity and nephrotoxicity. Free Radic Biol Med 2013; 65: 117-30.
184. Biasutto L, Marotta E, De Marchi U, Zoratti M, Paradisi C. Ester-based precursors to increase the bioavailability of quercetin. J Med Chem 2007; 50: 241-53.
185. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 2009, 133: 238-44.
186. Cai X, Fang Z, Dou J, Yu A, Zhai G. Bioavailability of quercetin: problems and promises. Curr Med Chem 2013; 20: 2572-82.